Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - ImmunoPrecise Antibodies

Drug Profile

Coronavirus vaccine - ImmunoPrecise Antibodies

Alternative Names: SARS-CoV-2 Vaccine - ImmunoPrecise Antibodies

Latest Information Update: 13 Mar 2020

At a glance

  • Originator ImmunoPrecise Antibodies
  • Class Antivirals; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 20 Feb 2020 Early research in COVID-2019-infections (Prevention) in USA (unspecified route)
  • 20 Feb 2020 Early research in COVID-2019-infections in USA (unspecified route)

Development Overview

Introduction

Coronavirus vaccine against SARS-CoV-2 coronavirus is being developed by ImmunoPrecise Antibodies, for the treatment and prevention of COVID-2019 infections. ImmunoPrecise Antibodies using its proprietary B cell Select progressive single-cell interrogation technology and the DeepDisplay discovery platform to develop the vaccine. ImmunoPrecise's proprietary B cell Select platform which screens millions of cells, and facilitates diverse antibody identification, with low manipulation. The platform is species and tissue independent, which helps generate antibodies from samples not possible using other methods. The platform exploits an animal's immune repertoire, enabling screening of any protein class, complex therapeutic targets, post-translational modifications, and small molecules. Early research is underway in the US.

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class Antivirals, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7 (Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research USA unspecified / unspecified ImmunoPrecise Antibodies 20 Feb 2020
COVID 2019 infections - - Research USA unspecified / unspecified ImmunoPrecise Antibodies 20 Feb 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
ImmunoPrecise Antibodies Originator Canada
ImmunoPrecise Antibodies Owner Canada

Development History

Event Date Update Type Comment
20 Feb 2020 Phase Change Early research in COVID-2019-infections (Prevention) in USA (unspecified route) Updated 13 Mar 2020
20 Feb 2020 Phase Change Early research in COVID-2019-infections in USA (unspecified route) Updated 13 Mar 2020
Back to top